Cholinesterase inhibitors in the “real world” setting: rivastigmine versus donepezil tolerability and effectiveness study
Journal Title: Archives of Medical Science - Year 2006, Vol 2, Issue 3
Abstract
Introduction: Comparative tolerability and effectiveness of donepezil and rivastigmine in clinical practice using a “real life” sample of patients diagnosed as having mild to moderate Alzheimer’s disease and treated in the memory clinic setting have not been properly studied to date. Material and methods: A retrospective, case records analysis of all patients (N=183) who had been prescribed either drug over the period of 3 years (1998-2000) and were seen for at least 6 months afterwards. Main outcome estimates were: for tolerability the likelihood to achieve recommended doses for both drugs and side effects profiles, for effectiveness clinical global impression of change (CGI) rating at 6 months after dose titration finished. Results: Numerically, more subjects on rivastigmine than on donepezil dropped out early due to side effects (14.6% vs 11.9%). A maximum approved dose (10 mg for donepezil and 12 mg for rivastigmine) has been achieved by significantly more patients on donepezil than on rivastigmine (p
Authors and Affiliations
Tomasz Sobow, Iwona Kloszewska
Keywords
Related Articles
- EP ID EP91184
- DOI -
- Views 187
- Downloads 0
Immunization coverage of health care workers against hepatitis B
Introduction: Hepatitis B virus (HBV) infection remains a serious risk for health care workers (HCWs). Vaccination of the group against HBV therefore is a central part of programs to prevent nosocomial infections in heal...
Surgical treatment of thoracic outlet syndrome: immediate and mid-term results
Postconditioning: a brief review
Preconditioning represents the most effective form of cardioprotection that can be induced to attenuate the injury accompanying a longer lasting ischemia (=index ischemia) of sufficient duration and severity to cause myo...
Anomalous superficial palmar arch: a cadaveric study with clinical implications
A practical method to determine the “atherogenic lipoprotein phenotype”